Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Ultimovacs (Norway) | Researchclopedia

Back to institutions

Ultimovacs (Norway)

Oslocompany

28

Works

876

Citations

19

h-index

Top Research Topics

Immunotherapy and Immune Responses Cancer Immunotherapy and Biomarkers Cancer Research and Treatments

Top Researchers

Gustav Gaudernack Oslo University Hospital

282 works10,862 citationsh-index: 58

Recent Research

The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): A randomized open-label phase 2 study

Paul Lorigan,Theresa Medina,et al.

20250 citations

CAR-T cell therapy research

vaccines and immunoinformatics approaches

Head and Neck Cancer Studies

Virus-based gene therapy research

Occupational and environmental lung diseases

Inflammatory Biomarkers in Disease Prognosis

Pleural and Pulmonary Diseases

T-cell and B-cell Immunology

COVID-19 Clinical Research Studies

Steinar Aamdal University of Oslo

190 works8,713 citationsh-index: 44

Sara M. Mangsbo Science for Life Laboratory

162 works3,237 citationsh-index: 34

Anna Bergqvist Ultimovacs (Norway)

80 works3,117 citationsh-index: 24

Jens Bjørheim Ultimovacs (Norway)

114 works820 citationsh-index: 13

Wenche Rasch Ultimovacs (Norway)

29 works657 citationsh-index: 12

Inflammation and limited adaptive immunity predict worse outcomes on immunotherapy in head and neck cancer

Lisa Paschold,Christoph Schultheiß,et al.

20255 citations

UV1 vaccination in pembrolizumab-treated patients with recurrent or metastatic head and neck cancer: A randomized multicenter phase 2 trial

Anna Brandt,Konrad Klinghammer,et al.

20254 citations

Preclinical development and clinical safety assessment of a synthetic peptide conjugate enabling endogenous antibody binding to promote innate receptor engagement

Erika Fletcher,Robert A. Cordfunke,et al.

20251 citations

Inflammatory signature and restriction of adaptive immunity are associated with unfavorable outcomes on immune checkpoint blockade in patients with advanced head and neck squamous cell carcinoma

Lisa Paschold,Christoph Schultheiß,et al.

20240 citations

UV1 cancer vaccine in pembrolizumab-treated patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma: results from the randomized phase 2 FOCUS trial

Anna Brandt,Konrad Klinghammer,et al.

20241 citations